Peptide Tyrosinase (Asp371) - HLA-A*0201 (YMDGTMSQV)

Tyrosinase protein: Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) is a human tyrosinase-derived (369-377) peptide by posttranslational conversion of the sequence YMNGTMSQV. Tyrosinase is an oxidase membrane-bound protein. Tyrosinase play a key role in the melanin synthesis pathway. Tyrosinase is presented on the surface of HLA-A*02:01 melanomas and also expressed in melanocytes. Tyrosinase has been still suggested to be a tumor antigen and might be implicated in improvement of immunotherapeutic strategies such as for efficient anticancer vaccine development. Applications of Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV): Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay. Peptide Tyrosinase (Asp371) – HLA-A*0201 (YMDGTMSQV) is also involved in experimental therapies of metastatic melanoma by allogeneic hematopoietic stem cell transplantation. In fact, cytotoxic T cells were generated from peripherical blood mononuclear cells (PBMCs) of HLA-A*02:01 healthy donors after being stimulated by injection of Asp371 antigen (2). This strategy raises issues which concern the graft versus tumor (GvT) effect and graft versus host disease (GvHD).